Bausch + Lomb drug fails in glaucoma, but a new use beckons
Bausch + Lomb drug fails in glaucoma, but a new use beckons Phil.Taylor Fri, 10/07/2026 - 09:52
Read the full articleYou might also wanna read
BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure
After 28 days of treatment, BL1107 did not meet its main goal of improving visual field scores in a study.
Asianet Newsable·13h ago
Dorzolamide/Brimonidine/Timolol Impact on Ocular Surface, Glaucoma Progression & Chatbot Follow-up: GLAUCO-TECH
Conditions : Primary Open-Angle Glaucoma (POAG); Ocular Hypertension Interventions : Combination Product: Preservative-free dorzolamide-timo
clinicaltrials.gov·2d ago
The costly failure of amyloid-beta drugs: A cautionary tale in pharmaceutical development
2.8k words, 12 minute reading time
owlposting.com·1mo ago以岭药业：厄贝沙坦化学原料药上市申请获批
36氪获悉，以岭药业公告，近日，公司全资孙公司万洋衡水制药有限公司（简称“衡水万洋”）收到国家药监局下发的《化学原料药上市申请批准通知书》，由衡水万洋提交的“厄贝沙坦”化学原料药上市申请已获批准。厄贝沙坦（Irbesartan）是血管紧张素Ⅱ受体抑制剂（ARB），用于原发性高血压
36氪·4d ago
Life Biosciences Conducts First Gene Therapy Trial to Reverse Cellular Aging in Patient with Glaucoma
For the first time ever, scientists are attempting to reverse cellular aging in a living patient. The target: incurable vision loss. The ris
popularmechanics.com·14d agoUCLA discovers first stroke rehabilitation drug to repair brain damage
Article URL: Comments URL: Points: 9 # Comments: 2
stemcell.ucla.edu·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.